Deciphering the role of innate immune NF-κB pathway in pancreatic cancer

Namrata Khurana, Paarth B. Dodhiawala, Ashenafi Bulle, Kian Huat Lim

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with no effective treatment option. A predominant hallmark of PDAC is the intense fibro-inflammatory stroma which not only physically collapses vasculature but also functionally suppresses anti-tumor immunity. Constitutive and induced activation of the NF-κB transcription factors is a major mechanism that drives inflammation in PDAC. While targeting this pathway is widely supported as a promising therapeutic strategy, clinical success is elusive due to a lack of safe and effective anti-NF-κB pathway therapeutics. Furthermore, the cell type-specific contribution of this pathway, specifically in neoplastic cells, stromal fibroblasts, and immune cells, has not been critically appraised. In this article, we highlighted seminal and recent literature on molecular mechanisms that drive NF-κB activity in each of these major cell types in PDAC, focusing specifically on the innate immune Toll-like/IL-1 receptor pathway. We reviewed recent evidence on the signaling interplay between the NF-κB and oncogenic KRAS signaling pathways in PDAC cells and their collective contribution to cancer inflammation. Lastly, we reviewed clinical trials on agents that target the NF-κB pathway and novel therapeutic strategies that have been proposed in preclinical studies.

Original languageEnglish
Article number2675
Pages (from-to)1-21
Number of pages21
Issue number9
StatePublished - Sep 2020


  • IRAK4
  • Inflammation
  • NF-κB
  • Pancreatic cancer
  • TAK1
  • TPL2


Dive into the research topics of 'Deciphering the role of innate immune NF-κB pathway in pancreatic cancer'. Together they form a unique fingerprint.

Cite this